Botox vs. Letybo: How South Korea’s #1 Neurotoxin Stacks Up Against the Gold Standard (2026 Guide)

If you have been hearing about Letybo recently and wondering how it compares to Botox, you are asking exactly the right question. Letybo is the newest FDA-approved cosmetic neuromodulator in the United States — approved for glabellar lines in February 2024 — but it has been the #1-selling type A botulinum toxin in South Korea for several years.

The short version: Letybo behaves clinically very much like Botox — same onset profile, same duration window, same 1:1 dosing, tight diffusion footprint. Where it diverges is on price (Letybo runs lower per unit) and on a specific BLESS phase-3 detail patients sometimes ask about: no neutralizing antibodies detected in repeat-dose subjects. This guide walks through every meaningful difference based on current FDA labels and the BLESS trial data.

What Botox and Letybo Actually Are

Both are purified type A botulinum toxin. Both block acetylcholine release at the neuromuscular junction, which relaxes the targeted facial muscle and smooths the overlying dynamic wrinkle.

The chemistry is more similar between Botox and Letybo than between Botox and most of the other newer entrants:

• Botox (onabotulinumtoxinA) — made by Allergan Aesthetics (an AbbVie company), FDA-approved for cosmetic glabellar lines in 2002. Formulated with a roughly 900 kDa accessory-protein complex and human serum albumin as a stabilizer.
• Letybo (letibotulinumtoxinA-wlbg) — made by Hugel America (the US arm of Hugel, Inc., a Korean biopharmaceutical company). FDA-approved for cosmetic glabellar lines in February 2024. Also formulated with a roughly 900 kDa accessory-protein complex and human serum albumin. Hugel’s manufacturing uses a proprietary process they describe as designed to maintain a high-purity active toxin yield.

The chemical similarity is part of why the clinical behavior is so close. Letybo is, by design and by clinical-data confirmation, the most “Botox-like” of the recent FDA approvals in the cosmetic neuromodulator space.

Onset: When Will You See Results?

Letybo is modestly faster to onset than Botox on average, though both reach peak effect on a similar timeline.

• Letybo onset: Median time to onset in the BLESS program was approximately 2.8 days, with most patients seeing softening at 2–3 days and peak effect at roughly 14 days.
• Botox onset: Most patients see softening at 3–7 days, with peak effect also around 10–14 days.

For routine maintenance, the onset difference is academic — both products are at or near peak by the 2-week mark. If you have a specific event in 5–10 days and want every day of head start, Letybo’s faster median onset can be a small advantage.

Duration: How Long Will Results Last?

Duration is essentially the same between the two products.

• Botox: Typical duration is 3–4 months for glabellar lines. The FDA label specifies that re-treatment should not be more frequent than every 3 months.
• Letybo: Typical duration is also 3–4 months. The BLESS I, II, and III phase-3 trials reported duration profiles that were comparable to onabotulinumtoxinA across multiple endpoints.

If duration is your single top priority, neither of these is the right answer — the longer-acting option to discuss with your injector is Daxxify, which is studied at a median of approximately 6 months. Between Botox and Letybo specifically, choose on cost, track record, and clinical fit; duration will be similar.

Dosing: The 1:1 Conversion

This is one of the simpler comparisons in the category, because the units are designed to be equivalent.

Per the FDA labels:

• Botox for glabellar lines: 20 units total, divided across 5 injection sites (4 units each).
• Letybo for glabellar lines: 20 units total, divided across 5 injection sites (4 units each).

The conversion is approximately 1:1. Clinically, your injector typically uses the same dose-per-area numbers they would have used for Botox. The FDA labels still warn that units between branded products are not formally interchangeable, so a competent injector documents which product was used and at what dose, but the practical math is straightforward.

This 1:1 simplicity is part of why Letybo has been an easy add for injectors who are already fluent in Botox dosing — they do not need to relearn the per-area unit counts.

Diffusion and Precision

Both Botox and Letybo have tight, precise diffusion profiles. In practical terms, Letybo behaves like Botox — appropriate for focal treatments like crow’s feet, lip flips, masseters, and other small targets where you do not want spread to neighboring muscle groups.

If you have heard that one of these “spreads more” than the other, that is not borne out by the head-to-head literature. Choose on cost, immunogenicity preferences, and your relationship with a specific injector.

Cost: What You Will Actually Pay in 2026

National 2026 averages, with the caveat that prices vary by city and clinic experience:

• Botox: roughly $12–$20 per unit, with most clinics in the $14–$16 range. A standard glabellar treatment (20 units) lands around $280–$320.
• Letybo: roughly $9–$15 per unit. A standard glabellar treatment (20 units) lands around $200–$300.

Because the dosing is 1:1, the per-unit price advantage flows directly through to per-treatment cost. A clinic pricing Botox at $14/unit and Letybo at $11/unit will charge $280 for a glabellar Botox treatment vs. $220 for the same Letybo treatment. That is a modest but real gap if you are treating multiple areas or coming in 3–4 times per year, and it is the single most common reason patients try Letybo.

One thing to confirm with any clinic: per-unit pricing should be transparent and the unit count for your treatment area should match the FDA-label-suggested ranges. Vague “per-area” pricing can hide undertreatment with any product, but it is especially worth asking about with newer, lower-priced products. At Naya Wellness, we quote per unit so you always know what you are paying for.

Side Effects, Safety, and the Antibody Question

The general side effect profile of Letybo mirrors Botox and the other type A toxins. In the BLESS trials and in post-marketing data, the most common adverse events were:

• Headache (3–8%)
• Injection-site reactions — bruising, redness, mild swelling (1–5%)
• Eyelid drooping (ptosis), uncommon in experienced hands
• Asymmetric brow position, typically correctable at a 2-week touch-up

One detail patients sometimes ask about: in the BLESS phase-3 immunogenicity assessment, no neutralizing antibodies were detected in repeat-dose subjects. Neutralizing antibodies bind and inactivate the toxin, theoretically reducing effectiveness over time. The absolute incidence of clinically meaningful neutralizing antibodies is very low at cosmetic doses for every product in the category, but Letybo’s clean BLESS signal is reassuring for patients who have specifically asked about this concern.

Both Botox and Letybo carry the same FDA boxed warning about the theoretical possibility of distant toxin spread. In cosmetic facial doses, this has not been a clinically meaningful concern across millions of treatments.

Who Is the Ideal Candidate for Each?

Botox may be the better fit if:

• You prefer the longest established US cosmetic track record
• You have a long-standing positive response to Botox and no specific reason to switch
• Your insurance or HSA paperwork is set up around a familiar product name
• You are budget-flexible and prioritize provider familiarity over per-unit savings

Letybo may be the better fit if:

• You are cost-sensitive and treating multiple areas or coming in multiple times per year
• You like the idea of a Botox-equivalent dosing experience without retraining your expectations
• You have specifically asked about neutralizing-antibody data and find BLESS reassuring
• You want to try a newer product without committing to a significantly different formulation

Can You Switch Between Botox and Letybo?

Yes. Because the two products are dosed 1:1 and behave very similarly clinically, switching between them is one of the simpler product transitions in the category. A few practical notes:

• Always tell your new injector which product you previously had, the dose, and roughly when. Even though the dosing is equivalent, documentation matters.
• You cannot combine the two products in the same treatment area in the same session.
• Most patients describe no perceptible difference when switching from Botox to Letybo or vice versa between sessions.
• Switching does not reduce the very small theoretical risk of antibody formation against either toxin.